Log In
Print
BCIQ
Print
Print this Print this
 

BL-9020

  Manage Alerts
Collapse Summary General Information
Company BioLineRx Ltd.
Description mAb against human natural cytotoxicity triggering receptor 1 (NCR1; NKP46; CD335)
Molecular Target Natural cytotoxicity triggering receptor 1 (NCR1) (NKP46) (CD335)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationDiabetes
Indication DetailsTreat Type I diabetes
Regulatory Designation
Partner JHL Biotech Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today